Stockscreener 앱 받기
45.30
1.07%
0.48
시간 외 거래:
45.30
전일 마감가:
$44.82
열려 있는:
$44.04
하루 거래량:
477.27K
Relative Volume:
0.72
시가총액:
$1.95B
수익:
-
순이익/손실:
$-38.99M
주가수익비율:
-14.95
EPS:
-3.03
순현금흐름:
$-24.94M
1주 성능:
+0.79%
1개월 성능:
-14.06%
6개월 성능:
+11.03%
1년 성능:
+12.55%
1일 변동 폭
$43.84
$45.46
1주일 범위
$43.84
$47.14
52주 변동 폭
$35.70
$60.92
Soleno Therapeutics Inc Stock (SLNO) Company Profile
명칭
Soleno Therapeutics Inc
전화
650-213-8444
주소
100 MARINE PARKWAY, SUITE 400, REDWOOD CITY, CA
SLNO을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
SLNO
Soleno Therapeutics Inc
|
45.30 | 1.95B | 0 | -38.99M | -24.94M | -2.9966 |
|
VRTX
Vertex Pharmaceuticals Inc
|
399.35 | 102.84B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
702.59 | 77.21B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
619.96 | 37.07B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
236.01 | 30.44B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
112.58 | 26.99B | 3.30B | -501.07M | 1.03B | -2.1146 |
Soleno Therapeutics Inc Stock (SLNO) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-12-02 | 재확인 | Robert W. Baird | Outperform |
| 2024-12-02 | 재확인 | Stifel | Buy |
| 2024-09-03 | 개시 | H.C. Wainwright | Buy |
| 2024-05-10 | 개시 | Robert W. Baird | Outperform |
| 2024-02-05 | 개시 | Piper Sandler | Overweight |
| 2024-01-23 | 개시 | Stifel | Buy |
| 2023-11-21 | 재개 | Guggenheim | Buy |
| 2020-09-29 | 개시 | Guggenheim | Buy |
| 2020-01-10 | 개시 | Craig Hallum | Buy |
| 2019-12-23 | 개시 | Oppenheimer | Outperform |
| 2018-02-13 | 재확인 | Maxim Group | Buy |
모두보기
Soleno Therapeutics Inc 주식(SLNO)의 최신 뉴스
Stock Traders Buy High Volume of Put Options on Soleno Therapeutics (NASDAQ:SLNO) - MarketBeat
(SLNO) Long Term Investment Analysis - Stock Traders Daily
Geode Capital Management LLC Buys 51,189 Shares of Soleno Therapeutics, Inc. (NASDAQ:SLNO) - Defense World
Soleno Therapeutics, Inc. (NASDAQ:SLNO) Stock Holdings Increased by Geode Capital Management LLC - MarketBeat
Barclays PLC Increases Position in Soleno Therapeutics, Inc. (NASDAQ:SLNO) - Defense World
Barclays PLC Acquires 31,467 Shares of Soleno Therapeutics, Inc. (NASDAQ:SLNO) - MarketBeat
Soleno Therapeutics, Inc. (NASDAQ:SLNO) Given Average Recommendation of “Buy” by Brokerages - Defense World
Soleno Therapeutics, Inc. (NASDAQ:SLNO) Given Average Recommendation of "Buy" by Brokerages - MarketBeat
Soleno Therapeutics is Now Oversold (SLNO) - Nasdaq
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Has $1.11 Million Stake in Soleno Therapeutics, Inc. (NASDAQ:SLNO) - Defense World
Teachers Retirement System of The State of Kentucky Buys Shares of 13,001 Soleno Therapeutics, Inc. (NASDAQ:SLNO) - MarketBeat
State Street Corp Has $57.67 Million Holdings in Soleno Therapeutics, Inc. (NASDAQ:SLNO) - Defense World
State Street Corp Buys 142,033 Shares of Soleno Therapeutics, Inc. (NASDAQ:SLNO) - MarketBeat
Soleno Therapeutics Enters Into $200 Million Debt Financing with Oxford Finance LLC - GlobeNewswire
Soleno Therapeutics Secures Massive $200M Financing Deal for Rare Disease Drug Development - StockTitan
When (SLNO) Moves Investors should Listen - Stock Traders Daily
Soleno Therapeutics: PDUFA Extension May Be An Opportunity, But Not For Me (NASDAQ:SLNO) - Seeking Alpha
Soleno Therapeutics (NASDAQ:SLNO) & Pixie Dust Technologies (NASDAQ:PXDT) Head to Head Survey - Defense World
Soleno Therapeutics' SWOT analysis: DCCR approval could reshape PWS treatment landscape By Investing.com - Investing.com South Africa
Soleno Therapeutics' SWOT analysis: DCCR approval could reshape PWS treatment landscape - Investing.com
Wellington Management Group LLP Acquires 290,135 Shares of Soleno Therapeutics, Inc. (NASDAQ:SLNO) - MarketBeat
FDA delays approval decision until March on DCCR for excessive hunger in PWS - Prader-Willi Syndrome News
SLNO Crosses Below Key Moving Average Level - Nasdaq
Charles Schwab Investment Management Inc. Acquires 130,080 Shares of Soleno Therapeutics, Inc. (NASDAQ:SLNO) - MarketBeat
Soleno Therapeutics, Inc. (NASDAQ:SLNO) Shares Acquired by Charles Schwab Investment Management Inc. - Defense World
Prader-Willi Syndrome Market Size, Share, Industry Growth, Key - openPR
Fmr LLC Acquires 665,363 Shares of Soleno Therapeutics, Inc. (NASDAQ:SLNO) - MarketBeat
Where are the Opportunities in (SLNO) - Stock Traders Daily
Polar Asset Management Partners Inc. Has $1.60 Million Stock Holdings in Soleno Therapeutics, Inc. (NASDAQ:SLNO) - MarketBeat
What is HC Wainwright’s Estimate for SLNO FY2024 Earnings? - Defense World
What is HC Wainwright's Forecast for SLNO FY2024 Earnings? - MarketBeat
Soleno Therapeutics, Inc. (NASDAQ:SLNO) Shares Bought by Janus Henderson Group PLC - MarketBeat
HighVista Strategies LLC Makes New $560,000 Investment in Soleno Therapeutics, Inc. (NASDAQ:SLNO) - MarketBeat
Holocene Advisors LP Increases Stock Position in Soleno Therapeutics, Inc. (NASDAQ:SLNO) - MarketBeat
Soleno Therapeutics (NASDAQ:SLNO) Given “Outperform” Rating at Robert W. Baird - Defense World
Wainwright retains stock target, buy rating on Soleno amid FDA delay - Investing.com Nigeria
Wainwright retains stock target, buy rating on Soleno amid FDA delay By Investing.com - Investing.com South Africa
Outperform rating maintained on Soleno Therapeutics stock, regulatory approval outlook strong - Investing.com UK
Martingale Asset Management L P Purchases Shares of 21,975 Soleno Therapeutics, Inc. (NASDAQ:SLNO) - MarketBeat
Soleno Therapeutics, Inc. (NASDAQ:SLNO) Short Interest Down 23.2% in November - MarketBeat
Baird maintains Outperform on Soleno, keeps $72 target By Investing.com - Investing.com Australia
Baird maintains Outperform on Soleno, keeps $72 target - Investing.com
Soleno Therapeutics, Inc. (NASDAQ:SLNO) Shares Sold by Vestal Point Capital LP - MarketBeat
Victory Capital Management Inc. Buys 2,782 Shares of Soleno Therapeutics, Inc. (NASDAQ:SLNO) - Defense World
Soleno Therapeutics Receives FDA Extension for DCCR Review - Defense World
Soleno Therapeutics Inc (SLNO-Q) QuotePress Release - The Globe and Mail
PDUFA target action date for Soleno’s DCCR extended by three months - The Pharma Letter
High Growth Tech Stocks to Watch in November 2024 - Simply Wall St
Soleno Therapeutics to Participate in Piper Sandler 36th Annual Healthcare Conference - The Manila Times
Soleno Therapeutics to Participate in Piper Sandler 36th Annual Healthcare Conference - GlobeNewswire Inc.
FDA delays decision of Soleno’s Prader-Willi syndrome drug - Yahoo Finance
Soleno Therapeutics Inc (SLNO) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.76%
1.06%
자본화:
|
볼륨(24시간):